Neuren Pharmaceuticals Limited (NEU.AX)
AUD 12.54
(-2.79%)
AUD 12.54
(-2.79%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 42.76 Million AUD | 2448.45% |
| 2022 | 1.67 Million AUD | 108.97% |
| 2021 | 803 Thousand AUD | 6.64% |
| 2020 | 753 Thousand AUD | 34.7% |
| 2019 | 559 Thousand AUD | -71.67% |
| 2018 | 1.97 Million AUD | 24.87% |
| 2017 | 1.58 Million AUD | -22.05% |
| 2016 | 2.02 Million AUD | -18.98% |
| 2015 | 2.5 Million AUD | -17.37% |
| 2014 | 3.02 Million AUD | 47.13% |
| 2013 | 2.05 Million AUD | -3.89% |
| 2012 | 2.14 Million AUD | 27.2% |
| 2011 | 1.68 Million AUD | -22.9% |
| 2010 | 2.18 Million AUD | -25.64% |
| 2009 | 2.93 Million AUD | -1.19% |
| 2008 | 2.97 Million AUD | -57.76% |
| 2007 | 7.03 Million AUD | 108.31% |
| 2006 | 3.37 Million AUD | 10.88% |
| 2005 | 3.04 Million AUD | -27.41% |
| 2004 | 4.19 Million AUD | 0.0% |
| 2003 | - AUD | 0.0% |
| 2002 | - AUD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 8.99 Million AUD | 0.0% |
| 2023 Q4 | 42.76 Million AUD | 0.0% |
| 2023 Q2 | 6.01 Million AUD | 0.0% |
| 2023 FY | 42.76 Million AUD | 2448.45% |
| 2022 Q2 | 1.09 Million AUD | 0.0% |
| 2022 Q4 | 1.67 Million AUD | 0.0% |
| 2022 FY | 1.67 Million AUD | 108.97% |
| 2021 FY | 803 Thousand AUD | 6.64% |
| 2021 Q4 | 803 Thousand AUD | 0.0% |
| 2021 Q2 | 2.35 Million AUD | 0.0% |
| 2020 Q2 | 601 Thousand AUD | 0.0% |
| 2020 FY | 753 Thousand AUD | 34.7% |
| 2020 Q4 | 753 Thousand AUD | 0.0% |
| 2019 Q2 | 1.32 Million AUD | 0.0% |
| 2019 FY | 559 Thousand AUD | -71.67% |
| 2019 Q4 | 559 Thousand AUD | 0.0% |
| 2018 Q2 | 1.29 Million AUD | 0.0% |
| 2018 Q4 | 1.97 Million AUD | 0.0% |
| 2018 FY | 1.97 Million AUD | 24.87% |
| 2017 Q4 | 1.58 Million AUD | 0.0% |
| 2017 Q2 | 565 Thousand AUD | 0.0% |
| 2017 FY | 1.58 Million AUD | -22.05% |
| 2016 Q4 | 2.02 Million AUD | 0.0% |
| 2016 FY | 2.02 Million AUD | -18.98% |
| 2016 Q2 | 1.64 Million AUD | 0.0% |
| 2015 Q4 | 2.5 Million AUD | 0.0% |
| 2015 FY | 2.5 Million AUD | -17.37% |
| 2015 Q2 | 3.38 Million AUD | 0.0% |
| 2014 FY | 3.02 Million AUD | 47.13% |
| 2014 Q2 | 2.45 Million AUD | 0.0% |
| 2014 Q4 | 3.02 Million AUD | 0.0% |
| 2013 Q2 | 2.23 Million AUD | 0.0% |
| 2013 FY | 2.05 Million AUD | -3.89% |
| 2013 Q4 | 2.05 Million AUD | 0.0% |
| 2012 FY | 2.14 Million AUD | 27.2% |
| 2012 Q4 | 2.14 Million AUD | 0.0% |
| 2011 Q4 | 1.68 Million AUD | 0.0% |
| 2011 FY | 1.68 Million AUD | -22.9% |
| 2010 Q4 | 2.18 Million AUD | 0.0% |
| 2010 FY | 2.18 Million AUD | -25.64% |
| 2009 FY | 2.93 Million AUD | -1.19% |
| 2009 Q4 | 2.93 Million AUD | 0.0% |
| 2008 Q4 | 2.97 Million AUD | 0.0% |
| 2008 FY | 2.97 Million AUD | -57.76% |
| 2007 Q4 | 7.03 Million AUD | 0.0% |
| 2007 FY | 7.03 Million AUD | 108.31% |
| 2006 FY | 3.37 Million AUD | 10.88% |
| 2006 Q4 | 3.37 Million AUD | 0.0% |
| 2005 Q4 | 3.04 Million AUD | 0.0% |
| 2005 FY | 3.04 Million AUD | -27.41% |
| 2004 FY | 4.19 Million AUD | 0.0% |
| 2003 FY | - AUD | 0.0% |
| 2002 FY | - AUD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| EZZ Life Science Holdings Limited | 4.22 Million AUD | -911.15% |
| Anatara Lifesciences Ltd | 306.84 Thousand AUD | -13836.171% |
| Zelira Therapeutics Limited | 9.35 Million AUD | -357.036% |
| Biome Australia Limited | 5.37 Million AUD | -695.848% |
| Patrys Limited | 691.36 Thousand AUD | -6085.3% |
| Orthocell Limited | 22.08 Million AUD | -93.65% |
| Imugene Limited | 33.14 Million AUD | -29.024% |
| Noxopharm Limited | 1.28 Million AUD | -3218.527% |
| PYC Therapeutics Limited | 10.18 Million AUD | -319.9% |
| Chimeric Therapeutics Limited | 12.8 Million AUD | -234.005% |
| Prescient Therapeutics Limited | 2.32 Million AUD | -1738.824% |
| Proteomics International Laboratories Limited | 1.62 Million AUD | -2530.072% |
| Cynata Therapeutics Limited | 1.17 Million AUD | -3551.665% |
| CSL Limited | 27.88 Billion AUD | 99.847% |
| Arovella Therapeutics Limited | 2.05 Million AUD | -1979.269% |
| Bio-Gene Technology Limited | 368.44 Thousand AUD | -11506.314% |
| Clinuvel Pharmaceuticals Limited | 28.11 Million AUD | -52.116% |
| Starpharma Holdings Limited | 8.69 Million AUD | -391.642% |
| Nanollose Limited | 465.64 Thousand AUD | -9083.645% |
| Memphasys Limited | 5.59 Million AUD | -664.664% |
| Invex Therapeutics Ltd | 431.63 Thousand AUD | -9807.328% |
| NeuroScientific Biopharmaceuticals Limited | 85.68 Thousand AUD | -49808.383% |
| Amplia Therapeutics Limited | 3.42 Million AUD | -1147.899% |
| Botanix Pharmaceuticals Limited | 3.73 Million AUD | -1045.823% |
| Island Pharmaceuticals Limited | 1.04 Million AUD | -3989.711% |
| Race Oncology Limited | 1.91 Million AUD | -2131.394% |
| Nyrada Inc. | 855.63 Thousand AUD | -4897.82% |
| Telix Pharmaceuticals Limited | 249.39 Million AUD | 82.853% |
| Dimerix Limited | 13.89 Million AUD | -207.802% |
| PharmAust Limited | 896.6 Thousand AUD | -4669.425% |
| Immutep Limited | 10.97 Million AUD | -289.477% |
| Clarity Pharmaceuticals Ltd | 8.33 Million AUD | -413.253% |
| Alterity Therapeutics Limited | 5.42 Million AUD | -688.158% |
| BTC Health Limited | 203.94 Thousand AUD | -20867.6% |
| Acrux Limited | 5.68 Million AUD | -651.943% |
| Biotron Limited | 737.5 Thousand AUD | -5698.31% |
| Tissue Repair Ltd | 1.35 Million AUD | -3065.51% |
| AdAlta Limited | 3.54 Million AUD | -1107.123% |
| Radiopharm Theranostics Limited | 44.68 Million AUD | 4.297% |
| Hexima Limited | 248.67 Thousand AUD | -17096.686% |
| AnteoTech Limited | 4.07 Million AUD | -949.333% |
| Paradigm Biopharmaceuticals Limited | 3.58 Million AUD | -1093.051% |
| Recce Pharmaceuticals Ltd | 15.89 Million AUD | -169.062% |
| Avecho Biotechnology Limited | 941.54 Thousand AUD | -4441.814% |
| Actinogen Medical Limited | 1.61 Million AUD | -2547.261% |
| Immuron Limited | 2.84 Million AUD | -1405.461% |
| Argenica Therapeutics Limited | 2.42 Million AUD | -1662.173% |